Inflammation Level (CRP) and Your Genetics

What Is C-Reactive Protein?

C-reactive protein (CRP) is a pentameric pattern-recognition protein synthesized and secreted by liver hepatocytes in response to inflammatory signals, primarily interleukin-6 (IL-6). Named for its ability to bind the C-polysaccharide of Streptococcus pneumoniae, CRP is a component of the innate immune system: it recognizes phosphocholine residues on the surface of damaged cells, apoptotic debris, and invading microorganisms, triggering complement activation and opsonization for phagocytic clearance. Circulating CRP levels are among the most sensitive blood markers of systemic inflammation, rising up to a thousandfold within 24 to 48 hours during acute infections or major tissue injury. At lower, persistently elevated concentrations, CRP reflects chronic low-grade inflammation associated with obesity, atherosclerosis, type 2 diabetes, and autoimmune conditions. High-sensitivity CRP (hsCRP) measurement is widely used in research and clinical settings as a population-level biomarker of cardiovascular and metabolic risk, and its genetics have been interrogated across some of the largest multi-cohort GWAS efforts in human biology.

Clinical CRP reference ranges: <1 mg/L (low); 1–3 mg/L (average); >3 mg/L (elevated chronic inflammation)

GWAS publications supporting this analysis: 9 multi-cohort studies across two decades

How CRP Production Is Regulated

The primary driver of hepatic CRP synthesis is IL-6, which is released from macrophages, adipose stromal cells, endothelial cells, and activated fibroblasts in response to inflammatory stimuli. IL-6 binds the IL-6 receptor (IL6R) on hepatocyte surfaces—or its soluble form in trans-signaling—activating the JAK1/JAK2-STAT3 pathway. Phosphorylated STAT3 translocates to the nucleus and directly upregulates CRP gene transcription at the chromosome 1q23.2 locus. IL-1β, acting through IL-1 receptor–NF-κB cascades, amplifies the hepatocyte response to IL-6. Counter-regulatory mechanisms include IL-4 (signaled via IL4R), which suppresses macrophage activation and IL-6 secretion, and IL-1 receptor antagonist (encoded by IL1RN), which competes with IL-1β for receptor occupancy. TNF-α, acting through TNFRSF1A, activates NF-κB to drive pro-inflammatory cytokine production upstream of IL-6 and CRP induction. Genetic variants that alter the efficiency of any step in this multi-layer regulatory circuit predictably shift the setpoint of baseline circulating CRP concentrations across the population.

Key Genes Prioritized by L2G Analysis

SORT1 (sortilin; L2G score 0.984) carries the highest per-gene L2G confidence in this analysis, at the well-replicated chromosome 1p13 locus. Sortilin is a hepatic intracellular sorting receptor that regulates secretion of VLDL and LDL particles as well as a range of other hepatic proteins. The chromosome 1p13 region is one of the most replicated human genetic loci for both LDL cholesterol and multiple acute-phase proteins, pointing to shared hepatic regulatory architecture connecting lipid metabolism and the inflammatory secretory response. CELSR2, a planar cell polarity receptor, shares this locus but carries lower L2G confidence than SORT1 for CRP specifically.

CRP (L2G 0.952, rank 3) appears as a high-confidence candidate at the chromosome 1q23.2 locus—the location of the structural gene encoding C-reactive protein itself. Variants at this locus function as cis-regulatory elements, altering CRP gene transcription efficiency in hepatocytes in response to IL-6 stimulation. This means that individuals with certain CRP locus variants produce more or less CRP protein per unit of inflammatory stimulus, independent of the upstream signaling that triggers CRP induction. The presence of the CRP gene among its own top GWAS loci is one of the clearest examples in population genetics of a protein's circulating concentration being co-regulated by variants within its own structural gene alongside trans-acting upstream regulators.

IL6R (IL-6 receptor; L2G 0.946, rank 4) encodes the surface receptor through which IL-6 drives the bulk of hepatic CRP synthesis via JAK/STAT3. The coding variant p.Asp358Ala (rs2228145) is among the most studied common variants in inflammatory genetics: it alters shedding of the IL-6 receptor, increasing soluble IL6R concentrations while reducing membrane-bound signaling efficiency. This variant has been used extensively as a genetic instrument in Mendelian randomization analyses of cardiovascular disease. The same receptor is the target of tocilizumab and sarilumab, FDA-approved biologics for rheumatoid arthritis and cytokine release syndrome, confirming that the IL-6 signaling axis captured in this GWAS locus is both biologically real and therapeutically actionable.

SERPINA1 (alpha-1 antitrypsin; L2G 0.966, rank 7) encodes a liver-secreted serine protease inhibitor that is itself classified as an acute-phase reactant, with circulating levels rising in parallel with CRP during inflammation. Common SERPINA1 variants associated with CRP in GWAS likely reflect shared hepatic regulatory dynamics among multiple acute-phase proteins synthesized in the same cells in response to the same stimuli. IL1RN (IL-1 receptor antagonist; L2G 0.936, rank 13) encodes the endogenous competitive antagonist of the IL-1 receptor; variants that alter IL1RN expression shift the balance between IL-1β-driven pro-inflammatory signaling and its counter-regulation, with downstream effects on IL-6 induction and CRP levels.

Additional high-confidence candidates include TNFRSF1A (TNF receptor type 1; L2G 0.952, rank 10), through which TNF-α drives NF-κB-mediated IL-6 production upstream of CRP synthesis; LYZ (lysozyme; L2G 0.968, rank 5), an antimicrobial enzyme secreted by activated macrophages that are the primary cellular source of inflammatory IL-6; IL4R (L2G 0.967, rank 6), the IL-4 receptor alpha chain through which anti-inflammatory IL-4 signaling suppresses macrophage M1 polarization and IL-6 secretion; and APOE (L2G 0.957, rank 1), which at the chromosome 19q13.3 locus ties the well-known lipid and neurological apolipoprotein E biology to the hepatic inflammatory milieu. Together, this multi-locus architecture spans independent chromosomal regions on chromosomes 1, 2, 4, 12, 14, 16, 19, and 20, demonstrating that baseline CRP levels are shaped by a genuinely multi-pathway genetic architecture.

What Your ExomeDNA Score Reflects

Your CRP genetic score reflects the cumulative influence of common variants on the genetic setpoint of baseline circulating CRP concentrations. A higher score indicates a greater genetic tendency toward elevated CRP, which in epidemiological studies is associated with cardiovascular, metabolic, and autoimmune health outcomes. Actual CRP is strongly influenced by non-genetic factors—obesity (adipose tissue constitutively releases IL-6), smoking, sleep disorders, periodontal disease, and chronic psychological stress all raise baseline CRP substantially. The genetic component captured by this score is real but modest relative to these lifestyle and environmental contributors; the score does not determine whether any individual's measured CRP is elevated or normal.

Research base: Robust.

Upstream pathway coverage: IL-6 axis (IL6R), TNF axis (TNFRSF1A), IL-1 counter-regulation (IL1RN), hepatic protein production (SORT1, SERPINA1), myeloid activation (LYZ)

Lifestyle and Environmental Context

CRP is one of the most lifestyle-responsive inflammatory biomarkers. Regular aerobic exercise reduces baseline CRP independently of weight change, likely through improved endothelial function and anti-inflammatory myokine release from muscle. Sustained weight loss—particularly reduction of visceral adiposity—substantially lowers the constitutive IL-6 output from adipose stromal cells, with direct downstream effects on hepatic CRP synthesis. Smoking cessation produces rapid and sustained CRP reduction. Mediterranean-type dietary patterns, characterized by high olive oil, fish, legumes, and vegetable intake with limited refined carbohydrates and processed meats, are consistently associated with lower baseline CRP in both observational and intervention studies. Chronic sleep restriction raises CRP through neuroendocrine and immune activation pathways, making sleep optimization an underappreciated anti-inflammatory lever.

Frequently Asked Questions

Why does the CRP gene itself appear as a genetic locus for CRP levels?

Variants at the CRP gene locus on chromosome 1q23 function as cis-regulatory elements that alter the efficiency with which CRP is transcribed in liver hepatocytes in response to IL-6 stimulation. Individuals with certain CRP locus variants produce more or less CRP protein per unit of inflammatory signal compared with carriers of other variants. The presence of the CRP gene itself among the top GWAS findings for circulating CRP levels is a compelling demonstration that a protein's serum concentration can be directly co-regulated by variants within its own structural gene locus, alongside trans-acting upstream regulators like IL6R.

Does a higher CRP genetic score mean I have chronic inflammation?

No. A polygenic score reflects a genetic tendency toward higher or lower baseline CRP levels; it does not measure actual circulating CRP at any point in time, and it does not indicate whether inflammation is present or absent. Measured CRP fluctuates substantially based on infections, injuries, lifestyle factors, and body composition. Many individuals with elevated CRP polygenic scores have measured CRP well within normal range, while individuals with lifestyle-driven inflammation can have elevated measurements regardless of their genetic background.

What does IL6R mean for both drug targets and genetic risk?

The IL6R p.Asp358Ala variant (rs2228145) alters IL-6 receptor shedding, shifting membrane-bound versus soluble receptor balance and modulating downstream JAK/STAT3 signaling strength. Tocilizumab and sarilumab—FDA-approved biologics—target the same receptor by blocking IL-6 binding. Mendelian randomization studies using IL6R variants as genetic instruments have been informative for testing whether reducing IL-6 signaling causally protects against cardiovascular events, providing a model for how genetic variants can mirror drug mechanisms in human study designs.

Is elevated CRP a cause of cardiovascular disease or a marker?

Mendelian randomization studies using CRP gene variants as genetic instruments have generally found that genetically elevated CRP does not substantially raise cardiovascular risk on its own, suggesting CRP may be a marker of the inflammatory state that contributes to cardiovascular disease rather than a direct mediator. By contrast, variants in IL6R that reduce IL-6 signaling—lowering CRP as a downstream consequence—are associated with reduced cardiovascular risk, pointing to upstream IL-6 pathway biology as a more likely causal driver of some cardiovascular outcomes.

What lifestyle changes most reliably lower CRP?

Regular aerobic exercise, smoking cessation, and sustained weight loss—particularly reduction of visceral adiposity—are the most consistently CRP-lowering lifestyle changes with clinical trial support. The Mediterranean dietary pattern is associated with meaningfully lower baseline CRP in both observational and intervention studies. Chronic sleep restriction (fewer than six hours per night) raises CRP through neuroendocrine immune activation, making sleep duration and quality a meaningful and often overlooked anti-inflammatory intervention.

What the Science Doesn't Know Yet

While the CRP gene locus, IL6R, and several other loci are robustly replicated across multiple large cohorts, the majority of the heritable component of circulating CRP remains unexplained by identified GWAS loci. Whether CRP is causally involved in specific disease processes—versus being a reliable marker of inflammation that itself causes those diseases—remains contested for conditions beyond cardiovascular disease. The interaction between genetic CRP variation and infectious burden, gut microbiome composition, and specific dietary and environmental exposures is largely uncharacterized. Current polygenic scores for CRP have been primarily derived in European-ancestry populations, limiting their transferability and the generalizability of association findings.